LRRK2 and Parkinson disease: Patients with PD carrying the G2019S LRRK2 mutation exhibited significantly higher CSF LRRK2 levels than healthy controls, sporadic PD patients, and G2019S LRRK2 non-manifesting carriers, supporting the hypothesis that mutated LRRK2’s pathogenicity stems from overabundance and overactivity [54].